BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 20496995)

  • 1. Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia.
    Shanafelt TD; Rabe KG; Kay NE; Zent CS; Call TG; Slager SL; Bowen DA; Schwager SM; Nowakowski GS
    Leuk Lymphoma; 2010 Jul; 51(7):1233-40. PubMed ID: 20496995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era.
    Nowakowski GS; Maurer MJ; Habermann TM; Ansell SM; Macon WR; Ristow KM; Allmer C; Slager SL; Witzig TE; Cerhan JR
    J Clin Oncol; 2010 Jan; 28(3):412-7. PubMed ID: 20008638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era.
    Brånvall E; Ekberg S; Eloranta S; Wästerlid T; Birmann BM; Smedby KE
    Br J Haematol; 2021 Nov; 195(4):552-560. PubMed ID: 34331461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.
    Perz J; Topaly J; Fruehauf S; Hensel M; Ho AD
    Leuk Lymphoma; 2002 Jan; 43(1):149-51. PubMed ID: 11908720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging information on the use of rituximab in chronic lymphocytic leukemia.
    Keating MJ; O'Brien S; Albitar M
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):70-4. PubMed ID: 11842391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia.
    Castro JE; Sandoval-Sus JD; Bole J; Rassenti L; Kipps TJ
    Leukemia; 2008 Nov; 22(11):2048-53. PubMed ID: 18754025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Cvetković RS; Perry CM
    Drugs; 2006; 66(6):791-820. PubMed ID: 16706552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia.
    Castro JE; James DF; Sandoval-Sus JD; Jain S; Bole J; Rassenti L; Kipps TJ
    Leukemia; 2009 Oct; 23(10):1779-89. PubMed ID: 19693094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
    Ennishi D; Asai H; Maeda Y; Shinagawa K; Ikeda K; Yokoyama M; Terui Y; Takeuchi K; Yoshino T; Matsuo K; Hatake K; Tanimoto M
    Ann Oncol; 2010 Jun; 21(6):1217-1221. PubMed ID: 19884246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.
    Pickartz T; Ringel F; Wedde M; Renz H; Klein A; von Neuhoff N; Dreger P; Kreuzer KA; Schmidt CA; Srock S; Schoeler D; Schriever F
    Exp Hematol; 2001 Dec; 29(12):1410-6. PubMed ID: 11750099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP.
    Samaras P; Heider H; Haile SR; Petrausch U; Schaefer NG; Siciliano RD; Meisel A; Mischo A; Zweifel M; Knuth A; Stenner-Liewen F; Renner C
    Ann Hematol; 2010 Aug; 89(8):783-7. PubMed ID: 20204361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Cvetković RS; Perry CM
    BioDrugs; 2006; 20(4):253-7. PubMed ID: 16831024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20.
    Winiarska M; Bil J; Wilczek E; Wilczynski GM; Lekka M; Engelberts PJ; Mackus WJ; Gorska E; Bojarski L; Stoklosa T; Nowis D; Kurzaj Z; Makowski M; Glodkowska E; Issat T; Mrowka P; Lasek W; Dabrowska-Iwanicka A; Basak GW; Wasik M; Warzocha K; Sinski M; Gaciong Z; Jakobisiak M; Parren PW; Golab J
    PLoS Med; 2008 Mar; 5(3):e64. PubMed ID: 18366248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of concomitant statin, metformin, or aspirin on rituximab treatment for diffuse large B-cell lymphoma.
    Koo YX; Tan DS; Tan IB; Tai DW; Ha T; Ong WS; Quek R; Tao M; Lim ST
    Leuk Lymphoma; 2011 Aug; 52(8):1509-16. PubMed ID: 21651435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancing therapy for chronic lymphocytic leukemia--the role of rituximab.
    Hillmen P
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):22-6. PubMed ID: 15042531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.
    Schriever F; Huhn D
    Drugs; 2003; 63(10):953-69. PubMed ID: 12699399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.
    Byrd JC; Murphy T; Howard RS; Lucas MS; Goodrich A; Park K; Pearson M; Waselenko JK; Ling G; Grever MR; Grillo-Lopez AJ; Rosenberg J; Kunkel L; Flinn IW
    J Clin Oncol; 2001 Apr; 19(8):2153-64. PubMed ID: 11304767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.